Physician profile
Sinu Paulose
NPI 1417411307
$3,821.59
in general payments reported to CMS, 2019-2025
35 companies · $33.86 in 2025
The $33.86 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,261 · 2022: $1,091 · 2023: $1,062 · 2024: $374 · 2025: $33.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $537.92 | 2021-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $515.42 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $345.13 | 2021-2023 | Eliquis |
| Lilly USA, LLC | $326.56 | 2021-2024 | Mounjaro, Trulicity |
| Novartis Pharmaceuticals Corporation | $165.67 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $141.62 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.63 | 2021-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $134.49 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $116.32 | 2023-2024 | Gemtesa |
| Pfizer INC. | $107.05 | 2021-2025 | |
| Gilead Sciences, INC. | $103.57 | 2021-2022 | |
| Astellas Pharma US INC | $99.46 | 2021-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.62 | 2021-2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $98.57 | 2021-2023 | Gvoke Hypopen |
| Amgen INC. | $86.41 | 2021-2025 | Krystexxa, Repatha, Otezla |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $79.98 | 2021-2024 | Airsupra, Farxiga |
| Sunovion Pharmaceuticals INC. | $76.79 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $72.87 | 2021-2022 | |
| Glaxosmithkline, LLC. | $62.15 | 2021 | |
| Exact Sciences Corporation | $53.85 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $53.82 | 2021 | |
| Vivus LLC | $52.53 | 2021-2022 | |
| Corcept Therapeutics | $43.21 | 2023 | Korlym |
| Dexcom, INC. | $38.94 | 2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $38.72 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $36.57 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $33.94 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $29.55 | 2021 | |
| Lundbeck LLC | $28.74 | 2023-2024 | Rexulti |
| Hikma Pharmaceuticals USA | $27.33 | 2021-2023 | Kloxxado, Mitigare, Ryaltris |
| Actelion Pharmaceuticals US, INC. | $23.08 | 2023 | Opsumit, Uptravi |
| Smith+Nephew, INC. | $17.73 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.78 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.43 | 2021 | |
| Pulmonx Corporation | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sinu Paulose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.